PRME Stock — Prime Medicine Inc.: Cash, EV, Pipeline

What they do

We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.65

Market cap

$843.4M

Cash

$95.1M

Enterprise value

$748.3M

Balance sheet

Cash	$95.1M
Debt	$0.0M
Net cash	$95.1M
Enterprise value	$748.3M
Basic shares	181.4M shares
Fully diluted shares	207.8M shares
Fully diluted market cap	$966.4M
Cash per share	$0.52
Quarterly burn	$41.0M
Cash runway	2.3 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

181.4M

Pre-funded warrants

0.0M

Options

21.7M

RSUs

—

Warrants

3.2M

Converts

—

Conv preferred

—

ESPP reserve

1.5M

FDSO

207.8M

Cap table as of 2026-07-31.

Price history

Loading PRME daily closes…

Loading price history…

Next catalyst

PM359 · Est. Apr 1, 2027 · half midpoint · guided in 8 wks

Recently reported

PM577a Phase 1/2 Mixed · 2026-10-05

wilson disease, wilson's disease, wilsons disease

Source release →

PM647 Positive · 2026-09-24

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	PM359 BLA submission for chronic granulomatous disease	Not disclosed	chronic granulomatous disease	H1 2027
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	PM577a global Phase 1/2 study in Wilson disease, initial clinical data	Phase 1/2	Wilson disease	2027
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	PM647 AATD program, initial clinical data	Not disclosed	AATD program	2027
Feb 12 - Mar 26 in 40 mo	PM359	Phase 2	Chronic Granulomatous Disease; Granulomatous Disease, Chronic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PM359

Phase 1 · Active Modality: ex vivo prime editing (autologous HSCT)

Target NCF1

Indications

Chronic granulomatous disease (CGD) (Phase 1)

Catalysts

— H1 2027

Status note Ex vivo Prime Editing for CGD correcting the ΔGT mutation in NCF1. Phase 1/2 ongoing in patients undergoing autologous hematopoietic stem cell transplantation; RMAT designation granted Jun 2026.

PM577a

Phase 1 · Active Modality: in vivo prime editor (LNP-delivered)

Aliases PM577

Target ATP7B

Indications

Wilson disease (H1069Q) (Phase 1)

Catalysts

— 2027

Status note Lead in vivo program. CTA cleared in New Zealand (Jun 2026) and IND cleared by FDA (Jul 2026); global Phase 1/2 trial initiating. Follow-on editors for additional ATP7B mutations in development.

PM647

Preclinical · Active Modality: in vivo prime editor (LNP-delivered)

Target SERPINA1

Indications

Alpha-1 antitrypsin deficiency (AATD) (Preclinical)

Catalysts

— Q3 2026
— 2027

Status note In vivo program for AATD; IND application submission and/or CTA filing on track for Q3 2026. (Jul 2026 arbitration: Tribunal confirmed PM647 is within the company's field under the Beam Collaboration Agreement.)

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PM577a
Lead indication	Wilson Disease
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07748403	Phase 2	Recruiting	Sponsor	PRME	—	Wilson Disease; Wilson's Disease; Wilsons Disease	—
NCT06559176	Phase 2	Enrolling by invitation	Sponsor	PRME	—	Chronic Granulomatous Disease; Granulomatous Disease, Chronic	—
NCT07226622	Not disclosed	Active, not recruiting	Sponsor	PRME	—	Wilson Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Prime Medicine, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Casdin Capital	3,167,175	no change	0.58%	2026-08-14
ADAR1 Capital Management	1,997,552	+24,270	0.35%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PRME — Prime Medicine Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

PRME — Prime Medicine Inc.